Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during
Citi has identified an attractive risk-reward scenario for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) in advance of headline data from a critical trial of its cardiac treatment Wainua, with results anticipated during